期刊
TRANSPLANTATION AND CELLULAR THERAPY
卷 27, 期 9, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtct.2021.05.025
关键词
Hematopoietic stem cell transplantation; Late effects; Long-term survivors; Metabolic syndrome; Pediatrics
资金
- Danish Childhood Cancer Foundation [2015-15, 2016-0261]
- Rigshospitalet Research Foundation
- Danish Cancer Society [R165-A10527]
- Danish Cancer Research Foundation
- Dagmar Marshall Foundation
- Hartmann Brothers Foundation [A30640]
- Finnish Cancer Society
- Finnish Foundation of Pediatric Research
- Helsinki University Research Foundation
- Swedish Childhood Cancer Foundation [PR2017-0037, TJ2015-0046]
- Swedish Research Council [2016-01296]
- Danish Karen Elise Jensen Foundation
- Swedish Research Council [2016-01296] Funding Source: Swedish Research Council
- Vinnova [2016-01296] Funding Source: Vinnova
This study aimed to investigate the prevalence and clinical presentation of MetS in male long-term survivors of pediatric HSCT. The study found that factors such as low-grade inflammation, altered fat distribution, and low testosterone levels may predispose individuals to MetS. Furthermore, MetS in HSCT survivors was associated with different clinical manifestations and risk factors compared to the general population.
Metabolic syndrome (MetS) is a growing concern in survivors of pediatric hematopoietic stem cell transplantation (HSCT), but little is known about the underlying mechanisms. This study aimed to determine the prevalence and clinical presentation of MetS in male long-term survivors of pediatric HSCT and to investigate predisposing factors, including low-grade inflammation, altered fat distribution, and low testosterone levels. We included 98 survivors age 19 to 47 years at a median follow-up of 18 years (range, 8 to 35 years) after pediatric HSCT. MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III criteria. The prevalence and clinical manifestations of MetS were compared between our cohort and a control group of males from the background population (n = 4767). Fat distribution was assessed by android/gynoid ratio from a whole-body dual-energy X-ray absorptiometry scan. Systemic inflammation was evaluated by IL-6 and high-sensitivity C-reactive protein (hsCRP). Serum testosterone levels were measured in morning samples. The prevalence of MetS was 30%, corresponding to the prevalence in the 50- to 80-year-old males from the background population. In individuals with MetS, hyperglycemia was more frequent in the HSCT survivors compared with age-matched controls with MetS (76% versus 20%; P < .001), whereas hypertension was more dominant in the control group with MetS (69% versus 93%; P = .01). In addition, normal or low body mass index was more commonly observed among HSCT survivors with MetS compared with age-matched controls with MetS (41% versus 11%; P = .002). MetS was more often associated with total body irradiation (TBI) compared with chemotherapy regimens (odds ratio [OR], 4.3; 95% confidence interval [CI], 1.2 to 24.4; P = .02), lower testosterone levels (OR, 5.4; 95% CI, 1.3 to 23.6; P = .02), higher IL-6 levels (OR, 1.8; 95% CI, 1.2 to 2.8; P = .004), and higher hsCRP levels (OR, 1.8; 95% CI, 1.3 to 2.6; P < .001) (estimates per 2-fold increase). In addition, an increased android/gynoid (AG) fat ratio was strongly associated with MetS (OR, 2.1; 95% CI, 1.5 to 2.9; P < .001), even though only 7% of patients met the criteria for increased abdominal circumference. Our results indicate an increased risk of MetS in early adulthood after pediatric HSCT. The clinical manifestations differed from those seen in age-matched controls with MetS, indicating different pathophysiology driven by hyperglycemia, altered fat distribution (despite no clinical abdominal obesity), and low-grade inflammation. Risk factors included TBI-based conditioning and low testosterone levels. These results underline the importance of continuous clinical assessment of the cardiometabolic risk profile and stress the presence of important dissimilarities in the pathophysiology of MetS in HSCT survivors compared with the background population. (c) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据